Key result
Personalized antiplatelet therapy reduces stent thrombosis risk in PCI patients with high platelet reactivity.
Why the study?
Some patients develop stent thrombosis or high on-treatment platelet reactivity despite using aspirin and clopidogrel, making screening for antiplatelet resistance and formulating personalized antiplatelet therapies necessary.
Screening for high on-treatment platelet reactivity and formulating personalized antiplatelet therapies is necessary to reduce thrombosis and bleeding risks in patients undergoing PCI.
Coronary atherosclerosis (or coronary heart disease [CHD]) is a common cardiovascular disease that seriously damages human health. Percutaneous coronary stent implantation represents the primary treatment option for severe CHD in clinical practice; meanwhile, dual antiplatelet therapy (DAPT) is widely used to reduce the risk of postoperative thrombosis. Although the mechanisms of action of the two most commonly used antiplatelet drugs, aspirin and clopidogrel, remain unclear, clinical studies have shown that some patients are susceptible to stent thrombosis-antiplatelet resistance (high on-treatment platelet reactivity [HTPR])-despite using these drugs. Therefore, screening for HTPR and formulating personalized antiplatelet therapies is necessary. Ticagrelor, indobufen, and rivaroxaban are the most common and safe antiplatelet drugs used in clinical practice, with broad application prospects. This review summarizes the mechanisms of action of existing antiplatelet drugs, reasons for personalized treatment, screening of antiplatelet reactions, and development of novel antiplatelet drugs.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2024) conducted a review in Coronary Heart Disease (CHD) undergoing interventional therapy. Personalized Antiplatelet Therapy was evaluated. Personalized antiplatelet therapy, utilizing novel drugs such as ticagrelor, rivaroxaban, and indobufen, is necessary to manage high on-treatment platelet reactivity and reduce the risk of stent thrombosis in patients with coronary heart disease undergoing percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: